GB2361061A - Single necleotide polymorphism in a pyruvate dehydrogenase kinase isoenzyme 2 (PDK2) in humans - Google Patents

Single necleotide polymorphism in a pyruvate dehydrogenase kinase isoenzyme 2 (PDK2) in humans

Info

Publication number
GB2361061A
GB2361061A GB0111826A GB0111826A GB2361061A GB 2361061 A GB2361061 A GB 2361061A GB 0111826 A GB0111826 A GB 0111826A GB 0111826 A GB0111826 A GB 0111826A GB 2361061 A GB2361061 A GB 2361061A
Authority
GB
United Kingdom
Prior art keywords
pdk2
polymorphism
pyruvate dehydrogenase
gene
necleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0111826A
Other versions
GB0111826D0 (en
Inventor
Rakesh Anand
John Edward Norris Morten
John Craig Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of GB0111826D0 publication Critical patent/GB0111826D0/en
Publication of GB2361061A publication Critical patent/GB2361061A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to polymorphisms in the human pyruvate dehydrogenase kinase isoenzyme 2(PDK2) gene, in particular to the discovery of a single nucleotide polymorphism in the coding region of the human PDK2 gene and two single nucleotide polymorphisms in the 3' untranslated region of the human PDK2 gene. The invention also relates to methods and materials for analysing allelic variation in the PDK2 gene, and to the use of PDK2 polymorphism in the diagnosis and treatment of diseases in which inhibition of PDK2 could be of therapeutic benefit, such as diabetes, obesity and sepsis.
GB0111826A 1998-12-23 1999-12-17 Single necleotide polymorphism in a pyruvate dehydrogenase kinase isoenzyme 2 (PDK2) in humans Withdrawn GB2361061A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9828256.9A GB9828256D0 (en) 1998-12-23 1998-12-23 Chemical compounds
PCT/GB1999/004305 WO2000039331A1 (en) 1998-12-23 1999-12-17 Single nucleotide polymorphism in a pyruvate dehydrogenase kinase isoenzyme 2 (pdk2) in humans

Publications (2)

Publication Number Publication Date
GB0111826D0 GB0111826D0 (en) 2001-07-04
GB2361061A true GB2361061A (en) 2001-10-10

Family

ID=10844741

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB9828256.9A Ceased GB9828256D0 (en) 1998-12-23 1998-12-23 Chemical compounds
GB0111826A Withdrawn GB2361061A (en) 1998-12-23 1999-12-17 Single necleotide polymorphism in a pyruvate dehydrogenase kinase isoenzyme 2 (PDK2) in humans

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB9828256.9A Ceased GB9828256D0 (en) 1998-12-23 1998-12-23 Chemical compounds

Country Status (5)

Country Link
EP (1) EP1141395A1 (en)
JP (1) JP2002533135A (en)
AU (1) AU1872700A (en)
GB (2) GB9828256D0 (en)
WO (1) WO2000039331A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1247860A1 (en) * 2001-04-06 2002-10-09 Pfizer Limited Crystal structure of pyruvate dehydrogenase kinase 2 (PDHK-2) and use thereof in methods for identifying and designing new ligands
WO2003018835A2 (en) * 2001-08-23 2003-03-06 Hvidovre Hospital Method for rapid detection of haplotypes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Biochemical J. Vol. 141 (3) 1974. Whitehouse S et.al. pages 761-774 *
Drug Devel. Res. Vol. 35 (3) 1995. Espinal J et.al. pages 130-136 *
J. Biol. Chem Vol. 270 (48) 1995. Gudi R et.al. pages 28989-28994 *

Also Published As

Publication number Publication date
GB0111826D0 (en) 2001-07-04
JP2002533135A (en) 2002-10-08
AU1872700A (en) 2000-07-31
GB9828256D0 (en) 1999-02-17
EP1141395A1 (en) 2001-10-10
WO2000039331A1 (en) 2000-07-06

Similar Documents

Publication Publication Date Title
WO2006063704A3 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2003038123A3 (en) Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
GB2342717A (en) Methods for analyzing ltc4 synthase polymorphisms and diagnostic use
GB0223038D0 (en) Therapeutic compounds
EP1562897A4 (en) Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
GB0225475D0 (en) Therapeutic agents
GB0223040D0 (en) Therapeutic compounds
TW200509937A (en) Novel compounds and their use in therapy
BRPI0411319A (en) therapeutically active compounds and their use
IS7669A (en) Methods for the Treatment or Prevention of 2,4-Pyrimidinediamine Compounds of Autoimmune Diseases
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2006063703A3 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
GB2361061A (en) Single necleotide polymorphism in a pyruvate dehydrogenase kinase isoenzyme 2 (PDK2) in humans
WO2001023410A3 (en) Drug target isogenes: polymorphisms in the interleukin 13 gene
WO2005108605A3 (en) Polymorphisms in abcb1 associated with a lack of clinical response to medicaments
WO2004008153A3 (en) Diagnostics and therapeutics for diseases associated with homo sapiens putative neurotransmitter receptor (pnr)
AU2002358580A1 (en) Methods of identifying genetic risk for and evaluating treatment of alzheimer's disease by determing single nucleotide polymorphisms
MA31664B1 (en) Oral formulations by structured editing of ion channel modulation compounds and methods of prevention of arrhythmias
WO2004038405A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
AU7402600A (en) New sequence variants of the human beta1-adrenoreceptor genes and use thereof
WO2000006769A3 (en) Human ccr-2 gene polymorphisms
WO2003096020A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8)
WO2003080098A3 (en) Diagnostics and therapeutics for diseases associated with homo sapiens formyl peptide receptor-like 2
GB0102408D0 (en) Chemical compounds
AU2003299314A1 (en) Fwd, pp2c1, adk3, cg3860, cdk4, cg7134, eip75b involved in the regulation of energy homeostasis

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)